Medline Inc. (MDLN)
| Market Cap | 48.11B |
| Revenue (ttm) | 29.94B +12.1% |
| Net Income | 701.00M -45.3% |
| EPS | 0.80 +998.4% |
| Shares Out | 1.31B |
| PE Ratio | 45.98 |
| Forward PE | 24.81 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,172,201 |
| Open | 36.20 |
| Previous Close | 36.59 |
| Day's Range | 36.04 - 36.99 |
| 52-Week Range | 32.49 - 50.88 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 44.60 (+21.89%) |
| Earnings Date | Aug 5, 2026 |
About MDLN
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. It operates through two segments: Medline Brand and Supply Chain Solutions. The Medline Brand segment procures and manufactures products from three product categories include surgical solutions, front line care, and laboratory and diagnostics. Its front line care offers med-surg products for patient-facing needs, including wound care products, exam g... [Read more]
Financial Performance
In 2025, Medline's revenue was $28.43 billion, an increase of 11.47% compared to the previous year's $25.51 billion. Earnings were $1.16 billion, a decrease of -3.42%.
Financial StatementsAnalyst Summary
According to 27 analysts, the average rating for MDLN stock is "Buy." The 12-month stock price target is $44.6, which is an increase of 21.89% from the latest price.
News
Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference
NORTHFIELD, Ill., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline”) (Nasdaq: MDLN) today announced that Jim Boyle, chief executive officer, and Mike Drazin, chief financial officer, are sche...
Kaplan Fox Notifies Medline Inc. (MDLN) Investors of a Securities Investigation into the Company
New York, New York--(Newsfile Corp. - September 2, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN)...
Kaplan Fox Announces a Securities Investigation into Medline Inc. (MDLN) - Investors Encouraged to Contact the Firm
New York, New York--(Newsfile Corp. - August 24, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN). ...
Kaplan Fox Encourages Investors of Medline Inc. (MDLN) to Contact the Firm to Learn About Their Legal Rights
New York, New York--(Newsfile Corp. - August 21, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN). ...
Kaplan Fox is Investigating Medline Inc. (MDLN) for Potential Violations of the Federal Securities Laws
New York, New York--(Newsfile Corp. - August 19, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN). ...
Medline price target lowered to $46 from $53 at JPMorgan
JPMorgan lowered the firm’s price target on Medline (MDLN) to $46 from $53 and keeps an Overweight rating on the shares.
Medline price target lowered to $55 from $62 at Tigress Financial
Tigress Financial lowered the firm’s price target on Medline (MDLN) to $55 from $62 and keeps a Buy rating on the shares. The firm views the recent fire-related weakness in…
Medline price target lowered to $45 from $53 at TD Cowen
TD Cowen lowered the firm’s price target on Medline (MDLN) to $45 from $53 and keeps a Buy rating on the shares. The firm updated its model following Q2 results…
Medline price target lowered to $48 from $52 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Medline (MDLN) to $48 from $52 and keeps an Overweight rating on the shares.
Medline price target lowered to $42 from $45 at Bairdq
Baird analyst Eric Coldwell lowered the firm’s price target on Medline (MDLN) to $42 from $45 and keeps an Outperform rating on the shares. The firm updated its model following…
Medline price target lowered to $37 from $42 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Medline (MDLN) to $37 from $42 and keeps a Hold rating on the shares.
Medline price target lowered to $39 from $48 at Evercore ISI
Evercore ISI lowered the firm’s price target on Medline (MDLN) to $39 from $48 and keeps an Outperform rating on the shares.
Medline price target lowered to $47 from $56 at Truist
Truist analyst Jailendra Singh lowered the firm’s price target on Medline (MDLN) to $47 from $56 and keeps a Buy rating on the shares.
Medline price target lowered to $45 from $50 at Stifel
Stifel lowered the firm’s price target on Medline (MDLN) to $45 from $50 and keeps a Buy rating on the shares.
Medline price target lowered to $47 from $54 at BMO Capital
BMO Capital analyst Sean Dodge lowered the firm’s price target on Medline (MDLN) to $47 from $54 and keeps an Outperform rating on the shares.
Medline price target lowered to $48 from $53 at Mizuho
Mizuho lowered the firm’s price target on Medline (MDLN) to $48 from $53 and keeps an Outperform rating on the shares.
Medline price target lowered to $46 from $53 at RBC Capital
RBC Capital lowered the firm’s price target on Medline (MDLN) to $46 from $53 and keeps an Outperform rating on the shares.
Medline price target lowered to $37 from $42 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Medline (MDLN) to $37 from $42 and keeps a Hold rating on the shares. The company saw continued sales momentum in Q2,…
Medline price target lowered to $45 from $55 at Citi
Citi lowered the firm’s price target on Medline (MDLN) to $45 from $55 and keeps a Buy rating on the shares. The firm updated its model for Q2 results and…
Medline reports Q2 adjusted EPS 50c, consensus 32c
Reports Q2 revenue $7.69B, consensus $7.51B. “Our second quarter results reflect strong execution of our growth strategy, and the operational resilience of our team,” said Jim Boyle, chief executive o...
Medline cuts FY26 adjusted EBITDA view to $3.3B-$3.4B from $3.5B-$3.6B
The company said, “The Company is updating its full year 2026 outlook for Organic Sales2 growth to 9.0% to 10.0%, compared to its previous outlook of 8.5% to 9.5%, reflecting…
Medline Earnings Call Transcript: Q2 2026
Q2 2026 saw 12% sales growth and a 13% rise in adjusted EBITDA, driven by strong demand and new customer wins. Guidance for organic sales was raised, but adjusted EBITDA was lowered due to inflation, Tracy fire costs, and operational investments. Margin pressures are being addressed with cost-saving initiatives.
Medline Earnings release: Q2 2026
Medline released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Medline Slides: Q2 2026
Medline has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Medline Quarterly report: Q2 2026
Medline has published its Q2 2026 quarterly earnings report on August 5, 2026.